PURMX has created a novel discovery platform, discovery of microRNAs optimized for safety and efficacy. In a Phase I clinical trial, we are evaluating our lead product, MIRX002 (miR-3140-3p), an optimized microRNA. MIRX002 targets multiple pathways involved in malignancies with minimal overlap with normal cellular functions. MIRX002 demonstrated potent anti-tumor activity in multiple animal models and a wide therapeutic window in GLP nonclinical safety. We look forward to introducing you to PURMX and MIRX002, including our ongoing clinical trial and future development opportunities.